KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Co-Diagnostics (CODX) Long-Term Deferred Tax (2020 - 2023)

Historic Long-Term Deferred Tax for Co-Diagnostics (CODX) over the last 3 years, with Q3 2023 value amounting to $4.3 million.

  • Co-Diagnostics' Long-Term Deferred Tax changed N/A to $4.3 million in Q3 2023 from the same period last year, while for Sep 2023 it was $4.3 million, marking a year-over-year change of. This contributed to the annual value of $7.2 million for FY2021, which is 122092.96% up from last year.
  • Latest data reveals that Co-Diagnostics reported Long-Term Deferred Tax of $4.3 million as of Q3 2023.
  • Co-Diagnostics' 5-year Long-Term Deferred Tax high stood at $7.2 million for Q4 2021, and its period low was $512552.0 during Q3 2021.
  • Its 3-year average for Long-Term Deferred Tax is $2.9 million, with a median of $2.0 million in 2023.
  • Examining YoY changes over the last 5 years, Co-Diagnostics' Long-Term Deferred Tax showed a top increase of 122092.96% in 2021 and a maximum decrease of 122092.96% in 2021.
  • Over the past 3 years, Co-Diagnostics' Long-Term Deferred Tax (Quarter) stood at $547224.0 in 2020, then skyrocketed by 1220.93% to $7.2 million in 2021, then tumbled by 40.9% to $4.3 million in 2023.
  • Its Long-Term Deferred Tax was $4.3 million in Q3 2023, compared to $2.0 million in Q2 2023 and $7.2 million in Q4 2021.